Monday 19 October 2026
Export FEED’s income statement to Excel — free account
ENvue Medical, Inc.
FEED Healthcare Medical Devices
ENvue Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue fell 51.6%, EPS grew 75.8%, free cash flow grew 19.8% and total debt fell 45.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.37
0.12
−24.49%
Follow FEED
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.80 | 0.57 | 3.59 | 1.65 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.46) | (0.54) | (1.81) | (1.18) | |
P/B ratio |
0.11 | 0.04 | 0.24 | 0.10 | |
Price to Tangible BV |
0.00 | 41.42 | 0.00 | 0.00 | |
EV/Sales |
(0.40) | (0.66) | 3.06 | 1.63 | |
EV/EBITDA |
0.12 | 0.16 | 0.00 | 0.00 | |
EV/Operating CF |
0.15 | 0.18 | (0.54) | (0.27) | |
EV/FCF |
0.15 | 0.18 | (0.54) | (0.27) | |
Quick Ratio |
0.62 | 0.68 | 0.38 | 0.18 | |
Current Ratio |
0.86 | 1.09 | 0.90 | 0.66 | |
Net Debt/EBITDA |
2.98 | 0.93 | 0.34 | 0.01 | |
Debt/Assets |
1.92% | 2.63% | 2.71% | 2.81% | |
Debt/Equity |
0.02 | 0.03 | 0.03 | 0.04 | |
Asset Turnover |
0.09 | 0.11 | 0.05 | 0.04 | |
Operating CF/Net income |
2.53 | 0.20 | 0.19 | 0.22 | |
Capex/Depreciation |
(0.11) | 0.00 | (0.08) | (0.12) | |
Interest Coverage |
0.80 | 9.60 | (47.58) | 9.55 | |
Research and Development Expense of Revenue |
30.61% | (1.60%) | 71.67% | 213.39% | |
Selling, General and Administrative Expense of Revenue |
306.79% | 1,056.09% | 488.21% | 1,965.69% | |
Intangible Assets out of Total Assets |
0.81 | 0.81 | 0.83 | 0.86 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 856.90% | |
Graham Net Nets |
(0.39) | (0.25) | (0.21) | (0.89) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2,148.77%) | (1,319.20%) | (320.60%) | (275.74%) | |
Free Cash Flow Yield |
(150.46%) | (650.59%) | (158.62%) | (370.51%) | |
Revenue per Share |
10.10 | 5.97 | 2.38 | 0.47 | |
Operating CF per Share |
(27.55) | (51.17) | (15.74) | (5.25) | |
Capex per Share |
(0.39) | (0.44) | (0.06) | (0.05) | |
Free Cash Flow per Share |
(27.94) | (51.61) | (15.80) | (5.30) | |
Cash per Share |
97.62 | 81.34 | 8.27 | 2.22 | |
Shareholders Equity per Share |
593.90 | 640.48 | 116.84 | 59.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
593.90 | 640.48 | 116.84 | 59.97 | |
Free Cash Flow |
(2.00) | (2.70) | (4.33) | (2.72) | |
Working Capital |
(1.63) | 0.61 | (0.67) | (2.49) | |
Capital Expenditures |
(0.03) | (0.02) | (0.02) | (0.03) | |
Net Current Asset Value |
(1.90) | (0.36) | (1.66) | (2.83) | |
EV/EBIT |
0.11 | 0.07 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.07 | 0.03 | 0.11 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.42 | 0.19 | 0.35 | 0.16 | |
Average Payables |
3.60 | 1.80 | 3.85 | 4.12 | |
Average Inventory |
2.25 | 2.26 | 2.14 | 2.39 | |
Average Assets |
29.53 | 22.38 | 41.99 | 44.94 | |
Average Common Equity |
22.17 | 17.06 | 33.85 | 35.62 |
Columns are period end dates